<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04207840</url>
  </required_header>
  <id_info>
    <org_study_id>API-E004-CL-I</org_study_id>
    <nct_id>NCT04207840</nct_id>
  </id_info>
  <brief_title>Study of Drug Exposure in Systemic Circulation of Primatene Mist by Oral Inhalation, Versus Epinephrine Injection by Intramuscular Injection and ProAir by Oral Inhalation in Healthy Individuals</brief_title>
  <official_title>Study of Drug Exposure in Systemic Circulation of Primatene Mist (0.25mg) by Oral Inhalation, Versus Epinephrine Injection (0.30mg) by Intramuscular Injection and ProAir (0.18mg) by Oral Inhalation in Healthy Individuals: A Randomized, Safety Evaluator-blind, Three-Treatment, Crossover, Fasting Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amphastar Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Amphastar Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess the drug exposure profile in systemic circulation of Primatene Mist by inhalation,&#xD;
      versus Epinephrine by intramuscular injection, and ProAir HFA by inhalation in healthy&#xD;
      adults.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 9, 2019</start_date>
  <completion_date type="Actual">December 23, 2019</completion_date>
  <primary_completion_date type="Actual">December 20, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>C[Max], Maximum Plasma Concentration of Albuterol or Epinephrine</measure>
    <time_frame>Samples were drawn at 30 minutes pre-dose and at 1, 2, 3, 5, 7, 9, 12, 15, 18, 21, 25, 30, 40, 50, 60, 70, 80, 90, 120 minutes, 4, 6, 8, 12, 18, and 24 hours post-dose.</time_frame>
    <description>Pharmacokinetic (PK) blood samples will be collected starting 30 minutes before dose and until 24 hours after dose. Plasma will be isolated for analyzing the concentrations of Albuterol and Epinephrine. C[max] will be obtained directly from the plot of PK curve.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC(0-tm)_TOT, Area Under the Curve (AUC) of Total (Exogenous and Endogenous, if Available) Active Product Ingredient (API) From Time 0 to Time (tm)</measure>
    <time_frame>Samples were drawn at 30 minutes pre-dose and at 1, 2, 3, 5, 7, 9, 12, 15, 18, 21, 25, 30, 40, 50, 60, 70, 80, 90, 120 minutes, 4, 6, 8, 12, 18, and 24 hours post-dose.</time_frame>
    <description>Pharmacokinetic (PK) blood samples will be collected starting 30 minutes before dose and until 24 hours after dose. Plasma will be isolated for analyzing the concentrations of Albuterol and Epinephrine. AUC(0-tm)_TOT will be calculated with the trapezoid method. Time tm is defined as the time after C[max] is reached where API concentration is reduced to the levels of the same day baseline.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC(0-tm)_DE, Area Under the Curve (AUC) of Exogenous Active Product Ingredient (API) From Time 0 to Time (tm)</measure>
    <time_frame>Samples were drawn at 30 minutes pre-dose and at 1, 2, 3, 5, 7, 9, 12, 15, 18, 21, 25, 30, 40, 50, 60, 70, 80, 90, 120 minutes, 4, 6, 8, 12, 18, and 24 hours post-dose.</time_frame>
    <description>Pharmacokinetic (PK) blood samples will be collected starting 30 minutes before dose and until 24 hours after dose. Plasma will be isolated for analyzing the concentrations of Albuterol and Epinephrine. AUC(0-tm)_DE will be calculated with the trapezoid method. Time tm is defined as the time after C[max] is reached where API concentration is reduced to the levels of the same day baseline.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC(0-inf), Area Under the Curve (AUC) of Albuterol or Epinephrine From Time 0 to Infinity</measure>
    <time_frame>Samples were drawn at 30 minutes pre-dose and at 1, 2, 3, 5, 7, 9, 12, 15, 18, 21, 25, 30, 40, 50, 60, 70, 80, 90, 120 minutes, 4, 6, 8, 12, 18, and 24 hours post-dose.</time_frame>
    <description>Pharmacokinetic (PK) blood samples will be collected starting 30 minutes before dose and until 24 hours after dose. Plasma will be isolated for analyzing the concentrations of Albuterol and Epinephrine. AUC(0-inf) will be calculated with the extrapolation method.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>t[Max], Time at Which Maximum Plasma Concentration of Albuterol or Epinephrine is Observed</measure>
    <time_frame>Samples were drawn at 30 minutes pre-dose and at 1, 2, 3, 5, 7, 9, 12, 15, 18, 21, 25, 30, 40, 50, 60, 70, 80, 90, 120 minutes, 4, 6, 8, 12, 18, and 24 hours post-dose.</time_frame>
    <description>Pharmacokinetic (PK) blood samples will be collected starting 30 minutes before dose and until 24 hours after dose. Plasma will be isolated for analyzing the concentrations of Albuterol and Epinephrine. t[max] will be obtained directly from the plot of PK curve when the maximum concentration is observed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t[1/2], Terminal Elimination Half-life of Albuterol or Epinephrine</measure>
    <time_frame>Samples were drawn at 30 minutes pre-dose and at 1, 2, 3, 5, 7, 9, 12, 15, 18, 21, 25, 30, 40, 50, 60, 70, 80, 90, 120 minutes, 4, 6, 8, 12, 18, and 24 hours post-dose.</time_frame>
    <description>Pharmacokinetic (PK) blood samples will be collected starting 30 minutes before dose and until 24 hours after dose. Plasma will be isolated for analyzing the concentrations of Albuterol and Epinephrine.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">28</enrollment>
  <condition>Pharmacokinetics</condition>
  <condition>Epinephrine</condition>
  <condition>Albuterol</condition>
  <condition>Asthma</condition>
  <condition>Anaphylaxis</condition>
  <arm_group>
    <arm_group_label>Primatene Mist, E004</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants who dosed with Primatene Mist.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Epinephrine Injection Auto-Injector (Generic of EpiPen)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants who were dosed with an Epinephrine Injection Auto-Injector.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Albuterol HFA</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants who dosed with Albuterol HFA.</description>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Epinephrine (0.125 mg/inhalation)</intervention_name>
    <description>Participants will self-administer 2 inhalations of Epinephrine (0.125 mg/inhalation) for a total dosage of 0.25 mg.</description>
    <arm_group_label>Primatene Mist, E004</arm_group_label>
    <other_name>Primatene Mist</other_name>
  </intervention>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Epinephrine Injection Auto-Injector (0.3mg/0.3mL)</intervention_name>
    <description>Participants will receive an intramuscular injection of Epinephrine via Auto-Injector (0.30 mg of epinephrine solution in 0.30 mL). The 0.30 mL dose will be given perpendicularly as a single deep intramuscular injection into the anterolateral aspect of the thigh.</description>
    <arm_group_label>Epinephrine Injection Auto-Injector (Generic of EpiPen)</arm_group_label>
    <other_name>Generic of EpiPen</other_name>
  </intervention>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Albuterol Sulfate (0.09 mg/inhalation)</intervention_name>
    <description>Participants will self-administer 2 inhalations of Albuterol Sulfate (0.09 mg/inhalation) for a total dosage of 0.18 mg.</description>
    <arm_group_label>Albuterol HFA</arm_group_label>
    <other_name>Albuterol HFA</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Agree to participate; understand and sign informed consent;&#xD;
&#xD;
          -  Male and female adults, aged 18 to 50 years, inclusive at Screening;&#xD;
&#xD;
          -  Generally healthy and medically stable, with no clinically significant abnormalities&#xD;
             based on physical examination and laboratory tests as determined by the Investigators;&#xD;
&#xD;
          -  Have good venous access;&#xD;
&#xD;
          -  Have normal resting blood pressure and normal heart rate (HR) without history of&#xD;
             syncope; a subject with out of range blood pressure may be enrolled in the study at&#xD;
             the discretion of the Principal Investigator;&#xD;
&#xD;
          -  Have a body mass index (BMI) of 18.0 - 30.0 kg/m^2;&#xD;
&#xD;
          -  Female candidates must be &gt;1 year post-menopausal or practicing a clinically&#xD;
             acceptable form of birth control and confirmed by negative urine or serum pregnancy&#xD;
             test at Screening;&#xD;
&#xD;
          -  Negative HIV-Ab, HBs-Ag and HCV-Ab;&#xD;
&#xD;
          -  Negative alcohol test (urine or breathalyzer);&#xD;
&#xD;
          -  Negative drug screening results;&#xD;
&#xD;
          -  Currently non-smoker; have not used any tobacco products for at least three (3) months&#xD;
             prior to Screening; and&#xD;
&#xD;
          -  Demonstrate proficiency in the use of MDI and a consistent inhalation time &gt;2.0&#xD;
             seconds after training, for at least three (3) times, with a maximum of 5 attempts.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Concurrent clinically significant cardiovascular, hematological, renal, neurologic,&#xD;
             hepatic, endocrine, psychiatric, or malignant diseases.&#xD;
&#xD;
          -  Known intolerance or hypersensitivity to any component of the study drugs (i.e.,&#xD;
             Epinephrine, Albuterol Sulfate or any sympathomimetic drugs, HFA-134a, thymol,&#xD;
             ethanol, ascorbic acid, nitric acid, and hydrochloric acid).&#xD;
&#xD;
          -  Upper or lower respiratory tract infection, or other systemic infection within 6 weeks&#xD;
             prior to Screening;&#xD;
&#xD;
          -  Clinically significant abnormalities in the screening/baseline ECG; prolonged&#xD;
             corrected QT interval (QTcF) on ECG: men &gt;450ms, women: &gt;470ms; single or multiple&#xD;
             premature ventricular contractions (PVC);&#xD;
&#xD;
          -  Abnormal thyroid function test (if TSH is out of range, refer to T3/T4 for thyroid&#xD;
             function assessment);&#xD;
&#xD;
          -  Subject has been on other investigational drug/device studies within 30 days of&#xD;
             Screening Visit or planned participation in another investigational drug trial at any&#xD;
             time during this trial;&#xD;
&#xD;
          -  Women who are pregnant or lactating or planning a pregnancy during the study period;&#xD;
&#xD;
          -  Subject has donated or lost &gt; 500 mL of blood within 3 months of Screening;&#xD;
&#xD;
          -  Evidence of alcohol or drug abuse or dependency within 6 months prior to screening; or&#xD;
&#xD;
          -  Use of any of the prohibited drugs without appropriate washout.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Amphastar Study Site 0035</name>
      <address>
        <city>Cypress</city>
        <state>California</state>
        <zip>90630</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>December 19, 2019</study_first_submitted>
  <study_first_submitted_qc>December 19, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 23, 2019</study_first_posted>
  <results_first_submitted>January 25, 2021</results_first_submitted>
  <results_first_submitted_qc>March 4, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">March 30, 2021</results_first_posted>
  <last_update_submitted>March 4, 2021</last_update_submitted>
  <last_update_submitted_qc>March 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Aspiration</mesh_term>
    <mesh_term>Anaphylaxis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epinephrine</mesh_term>
    <mesh_term>Racepinephrine</mesh_term>
    <mesh_term>Albuterol</mesh_term>
    <mesh_term>Epinephryl borate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Access to patient level data and supporting clinical documents may be requested by qualified researchers. Requests will be reviewed on the basis of scientific merit. Patient data will be de-identified to protect the privacy of trial patients in line with applicable laws and regulations.</ipd_description>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>November 8, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/40/NCT04207840/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>October 13, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/40/NCT04207840/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Participants were randomized to receive all 3 treatments over 3 treatment periods in a crossover design.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>A-B-C</title>
          <description>Subjects received one of the three treatments during each study visit. Visit 1: Treatment A: Two (2) inhalations of Primatene Mist (0.125 mg of epinephrine per inhalation), for a total dosage of 0.25 mg; Visit 2: Treatment B: Intramuscular injection of Epinephrine via Auto-Injector (0.30 mg of epinephrine solution in 0.30 mL), for a total dosage of 0.30 mg; Visit 3: Treatment C: Two (2) inhalations of Albuterol HFA (0.09 mg of albuterol sulfate per inhalation), for a total dosage of 0.18 mg.</description>
        </group>
        <group group_id="P2">
          <title>B-C-A</title>
          <description>Subjects received one of the three treatments during each study visit. Visit 1: Treatment B: Intramuscular injection of Epinephrine via Auto-Injector (0.30 mg of epinephrine solution in 0.30 mL), for a total dosage of 0.30 mg; Visit 2: Treatment C: Two (2) inhalations of Albuterol HFA (0.09 mg of albuterol sulfate per inhalation), for a total dosage of 0.18 mg; Visit 3: Treatment A: Two (2) inhalations of Primatene Mist (0.125 mg of epinephrine per inhalation), for a total dosage of 0.25 mg.</description>
        </group>
        <group group_id="P3">
          <title>C-A-B</title>
          <description>Subjects received one of the three treatments during each study visit. Visit 1: Treatment C: Two (2) inhalations of Albuterol HFA (0.09 mg of albuterol sulfate per inhalation), for a total dosage of 0.18 mg; Visit 2: Treatment A: Two (2) inhalations of Primatene Mist (0.125 mg of epinephrine per inhalation), for a total dosage of 0.25 mg; Visit 3: Treatment B: Intramuscular injection of Epinephrine via Auto-Injector (0.30 mg of epinephrine solution in 0.30 mL), for a total dosage of 0.30 mg.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Treatment Period 1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Washout Period 1 (2-7 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Treatment Period 2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Washout Period 2 (2-7 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Treatment Period 3</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>All Study Participants</title>
          <description>All participants who have been randomized.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="28"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37.1" spread="7.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African-American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>C[Max], Maximum Plasma Concentration of Albuterol or Epinephrine</title>
        <description>Pharmacokinetic (PK) blood samples will be collected starting 30 minutes before dose and until 24 hours after dose. Plasma will be isolated for analyzing the concentrations of Albuterol and Epinephrine. C[max] will be obtained directly from the plot of PK curve.</description>
        <time_frame>Samples were drawn at 30 minutes pre-dose and at 1, 2, 3, 5, 7, 9, 12, 15, 18, 21, 25, 30, 40, 50, 60, 70, 80, 90, 120 minutes, 4, 6, 8, 12, 18, and 24 hours post-dose.</time_frame>
        <population>Per Protocol Population, defined as all subjects who have received all study medications and are evaluable for all treatments.</population>
        <group_list>
          <group group_id="O1">
            <title>Primatene Mist, E004</title>
            <description>Participants who dosed with Primatene Mist.&#xD;
Epinephrine (0.125 mg/inhalation): Participants will self-administer 2 inhalations of Epinephrine (0.125 mg/inhalation) for a total dosage of 0.25 mg.</description>
          </group>
          <group group_id="O2">
            <title>Epinephrine Injection Auto-Injector (Generic of EpiPen)</title>
            <description>Participants who were dosed with an Epinephrine Injection Auto-Injector.&#xD;
Epinephrine Injection Auto-Injector (0.3mg/0.3mL): Participants will receive an intramuscular injection of Epinephrine via Auto-Injector (0.30 mg of epinephrine solution in 0.30 mL). The 0.30 mL dose will be given perpendicularly as a single deep intramuscular injection into the anterolateral aspect of the thigh.</description>
          </group>
          <group group_id="O3">
            <title>Albuterol HFA</title>
            <description>Participants who dosed with Albuterol HFA.&#xD;
Albuterol Sulfate (0.09 mg/inhalation): Participants will self-administer 2 inhalations of Albuterol Sulfate (0.09 mg/inhalation) for a total dosage of 0.18 mg.</description>
          </group>
        </group_list>
        <measure>
          <title>C[Max], Maximum Plasma Concentration of Albuterol or Epinephrine</title>
          <description>Pharmacokinetic (PK) blood samples will be collected starting 30 minutes before dose and until 24 hours after dose. Plasma will be isolated for analyzing the concentrations of Albuterol and Epinephrine. C[max] will be obtained directly from the plot of PK curve.</description>
          <population>Per Protocol Population, defined as all subjects who have received all study medications and are evaluable for all treatments.</population>
          <units>pg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="240.8" spread="2.4"/>
                    <measurement group_id="O2" value="704.8" spread="1.8"/>
                    <measurement group_id="O3" value="599.8" spread="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC(0-tm)_TOT, Area Under the Curve (AUC) of Total (Exogenous and Endogenous, if Available) Active Product Ingredient (API) From Time 0 to Time (tm)</title>
        <description>Pharmacokinetic (PK) blood samples will be collected starting 30 minutes before dose and until 24 hours after dose. Plasma will be isolated for analyzing the concentrations of Albuterol and Epinephrine. AUC(0-tm)_TOT will be calculated with the trapezoid method. Time tm is defined as the time after C[max] is reached where API concentration is reduced to the levels of the same day baseline.</description>
        <time_frame>Samples were drawn at 30 minutes pre-dose and at 1, 2, 3, 5, 7, 9, 12, 15, 18, 21, 25, 30, 40, 50, 60, 70, 80, 90, 120 minutes, 4, 6, 8, 12, 18, and 24 hours post-dose.</time_frame>
        <population>Per Protocol Population, defined as all subjects who have received all study medications and are evaluable for all treatments.</population>
        <group_list>
          <group group_id="O1">
            <title>Primatene Mist, E004</title>
            <description>Participants who dosed with Primatene Mist.&#xD;
Epinephrine (0.125 mg/inhalation): Participants will self-administer 2 inhalations of Epinephrine (0.125 mg/inhalation) for a total dosage of 0.25 mg.</description>
          </group>
          <group group_id="O2">
            <title>Epinephrine Injection Auto-Injector (Generic of EpiPen)</title>
            <description>Participants who were dosed with an Epinephrine Injection Auto-Injector.&#xD;
Epinephrine Injection Auto-Injector (0.3mg/0.3mL): Participants will receive an intramuscular injection of Epinephrine via Auto-Injector (0.30 mg of epinephrine solution in 0.30 mL). The 0.30 mL dose will be given perpendicularly as a single deep intramuscular injection into the anterolateral aspect of the thigh.</description>
          </group>
          <group group_id="O3">
            <title>Albuterol HFA</title>
            <description>Participants who dosed with Albuterol HFA.&#xD;
Albuterol Sulfate (0.09 mg/inhalation): Participants will self-administer 2 inhalations of Albuterol Sulfate (0.09 mg/inhalation) for a total dosage of 0.18 mg.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC(0-tm)_TOT, Area Under the Curve (AUC) of Total (Exogenous and Endogenous, if Available) Active Product Ingredient (API) From Time 0 to Time (tm)</title>
          <description>Pharmacokinetic (PK) blood samples will be collected starting 30 minutes before dose and until 24 hours after dose. Plasma will be isolated for analyzing the concentrations of Albuterol and Epinephrine. AUC(0-tm)_TOT will be calculated with the trapezoid method. Time tm is defined as the time after C[max] is reached where API concentration is reduced to the levels of the same day baseline.</description>
          <population>Per Protocol Population, defined as all subjects who have received all study medications and are evaluable for all treatments.</population>
          <units>pg/mL x hr</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.8" spread="3.1"/>
                    <measurement group_id="O2" value="509.9" spread="1.5"/>
                    <measurement group_id="O3" value="3332.3" spread="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC(0-tm)_DE, Area Under the Curve (AUC) of Exogenous Active Product Ingredient (API) From Time 0 to Time (tm)</title>
        <description>Pharmacokinetic (PK) blood samples will be collected starting 30 minutes before dose and until 24 hours after dose. Plasma will be isolated for analyzing the concentrations of Albuterol and Epinephrine. AUC(0-tm)_DE will be calculated with the trapezoid method. Time tm is defined as the time after C[max] is reached where API concentration is reduced to the levels of the same day baseline.</description>
        <time_frame>Samples were drawn at 30 minutes pre-dose and at 1, 2, 3, 5, 7, 9, 12, 15, 18, 21, 25, 30, 40, 50, 60, 70, 80, 90, 120 minutes, 4, 6, 8, 12, 18, and 24 hours post-dose.</time_frame>
        <population>Per Protocol Population, defined as all subjects who have received all study medications and are evaluable for all treatments.</population>
        <group_list>
          <group group_id="O1">
            <title>Primatene Mist, E004</title>
            <description>Participants who dosed with Primatene Mist.&#xD;
Epinephrine (0.125 mg/inhalation): Participants will self-administer 2 inhalations of Epinephrine (0.125 mg/inhalation) for a total dosage of 0.25 mg.</description>
          </group>
          <group group_id="O2">
            <title>Epinephrine Injection Auto-Injector (Generic of EpiPen)</title>
            <description>Participants who were dosed with an Epinephrine Injection Auto-Injector.&#xD;
Epinephrine Injection Auto-Injector (0.3mg/0.3mL): Participants will receive an intramuscular injection of Epinephrine via Auto-Injector (0.30 mg of epinephrine solution in 0.30 mL). The 0.30 mL dose will be given perpendicularly as a single deep intramuscular injection into the anterolateral aspect of the thigh.</description>
          </group>
          <group group_id="O3">
            <title>Albuterol HFA</title>
            <description>Participants who dosed with Albuterol HFA.&#xD;
Albuterol Sulfate (0.09 mg/inhalation): Participants will self-administer 2 inhalations of Albuterol Sulfate (0.09 mg/inhalation) for a total dosage of 0.18 mg.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC(0-tm)_DE, Area Under the Curve (AUC) of Exogenous Active Product Ingredient (API) From Time 0 to Time (tm)</title>
          <description>Pharmacokinetic (PK) blood samples will be collected starting 30 minutes before dose and until 24 hours after dose. Plasma will be isolated for analyzing the concentrations of Albuterol and Epinephrine. AUC(0-tm)_DE will be calculated with the trapezoid method. Time tm is defined as the time after C[max] is reached where API concentration is reduced to the levels of the same day baseline.</description>
          <population>Per Protocol Population, defined as all subjects who have received all study medications and are evaluable for all treatments.</population>
          <units>pg/mL x hr</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.4" spread="3.6"/>
                    <measurement group_id="O2" value="396.3" spread="1.6"/>
                    <measurement group_id="O3" value="3332.3" spread="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC(0-inf), Area Under the Curve (AUC) of Albuterol or Epinephrine From Time 0 to Infinity</title>
        <description>Pharmacokinetic (PK) blood samples will be collected starting 30 minutes before dose and until 24 hours after dose. Plasma will be isolated for analyzing the concentrations of Albuterol and Epinephrine. AUC(0-inf) will be calculated with the extrapolation method.</description>
        <time_frame>Samples were drawn at 30 minutes pre-dose and at 1, 2, 3, 5, 7, 9, 12, 15, 18, 21, 25, 30, 40, 50, 60, 70, 80, 90, 120 minutes, 4, 6, 8, 12, 18, and 24 hours post-dose.</time_frame>
        <population>Per Protocol Population, defined as all subjects who have received all study medications and are evaluable for all treatments.</population>
        <group_list>
          <group group_id="O1">
            <title>Primatene Mist, E004</title>
            <description>Participants who dosed with Primatene Mist.&#xD;
Epinephrine (0.125 mg/inhalation): Participants will self-administer 2 inhalations of Epinephrine (0.125 mg/inhalation) for a total dosage of 0.25 mg.</description>
          </group>
          <group group_id="O2">
            <title>Epinephrine Injection Auto-Injector (Generic of EpiPen)</title>
            <description>Participants who were dosed with an Epinephrine Injection Auto-Injector.&#xD;
Epinephrine Injection Auto-Injector (0.3mg/0.3mL): Participants will receive an intramuscular injection of Epinephrine via Auto-Injector (0.30 mg of epinephrine solution in 0.30 mL). The 0.30 mL dose will be given perpendicularly as a single deep intramuscular injection into the anterolateral aspect of the thigh.</description>
          </group>
          <group group_id="O3">
            <title>Albuterol HFA</title>
            <description>Participants who dosed with Albuterol HFA.&#xD;
Albuterol Sulfate (0.09 mg/inhalation): Participants will self-administer 2 inhalations of Albuterol Sulfate (0.09 mg/inhalation) for a total dosage of 0.18 mg.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC(0-inf), Area Under the Curve (AUC) of Albuterol or Epinephrine From Time 0 to Infinity</title>
          <description>Pharmacokinetic (PK) blood samples will be collected starting 30 minutes before dose and until 24 hours after dose. Plasma will be isolated for analyzing the concentrations of Albuterol and Epinephrine. AUC(0-inf) will be calculated with the extrapolation method.</description>
          <population>Per Protocol Population, defined as all subjects who have received all study medications and are evaluable for all treatments.</population>
          <units>pg/mL x hr</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.4" spread="3.6"/>
                    <measurement group_id="O2" value="411.4" spread="1.7"/>
                    <measurement group_id="O3" value="3650.4" spread="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>t[Max], Time at Which Maximum Plasma Concentration of Albuterol or Epinephrine is Observed</title>
        <description>Pharmacokinetic (PK) blood samples will be collected starting 30 minutes before dose and until 24 hours after dose. Plasma will be isolated for analyzing the concentrations of Albuterol and Epinephrine. t[max] will be obtained directly from the plot of PK curve when the maximum concentration is observed.</description>
        <time_frame>Samples were drawn at 30 minutes pre-dose and at 1, 2, 3, 5, 7, 9, 12, 15, 18, 21, 25, 30, 40, 50, 60, 70, 80, 90, 120 minutes, 4, 6, 8, 12, 18, and 24 hours post-dose.</time_frame>
        <population>Per Protocol Population, defined as all subjects who have received all study medications and are evaluable for all treatments.</population>
        <group_list>
          <group group_id="O1">
            <title>Primatene Mist, E004</title>
            <description>Participants who dosed with Primatene Mist.&#xD;
Epinephrine (0.125 mg/inhalation): Participants will self-administer 2 inhalations of Epinephrine (0.125 mg/inhalation) for a total dosage of 0.25 mg.</description>
          </group>
          <group group_id="O2">
            <title>Epinephrine Injection Auto-Injector (Generic of EpiPen)</title>
            <description>Participants who were dosed with an Epinephrine Injection Auto-Injector.&#xD;
Epinephrine Injection Auto-Injector (0.3mg/0.3mL): Participants will receive an intramuscular injection of Epinephrine via Auto-Injector (0.30 mg of epinephrine solution in 0.30 mL). The 0.30 mL dose will be given perpendicularly as a single deep intramuscular injection into the anterolateral aspect of the thigh.</description>
          </group>
          <group group_id="O3">
            <title>Albuterol HFA</title>
            <description>Participants who dosed with Albuterol HFA.&#xD;
Albuterol Sulfate (0.09 mg/inhalation): Participants will self-administer 2 inhalations of Albuterol Sulfate (0.09 mg/inhalation) for a total dosage of 0.18 mg.</description>
          </group>
        </group_list>
        <measure>
          <title>t[Max], Time at Which Maximum Plasma Concentration of Albuterol or Epinephrine is Observed</title>
          <description>Pharmacokinetic (PK) blood samples will be collected starting 30 minutes before dose and until 24 hours after dose. Plasma will be isolated for analyzing the concentrations of Albuterol and Epinephrine. t[max] will be obtained directly from the plot of PK curve when the maximum concentration is observed.</description>
          <population>Per Protocol Population, defined as all subjects who have received all study medications and are evaluable for all treatments.</population>
          <units>min</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6" spread="3.0"/>
                    <measurement group_id="O2" value="8.3" spread="2.7"/>
                    <measurement group_id="O3" value="21.8" spread="3.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>t[1/2], Terminal Elimination Half-life of Albuterol or Epinephrine</title>
        <description>Pharmacokinetic (PK) blood samples will be collected starting 30 minutes before dose and until 24 hours after dose. Plasma will be isolated for analyzing the concentrations of Albuterol and Epinephrine.</description>
        <time_frame>Samples were drawn at 30 minutes pre-dose and at 1, 2, 3, 5, 7, 9, 12, 15, 18, 21, 25, 30, 40, 50, 60, 70, 80, 90, 120 minutes, 4, 6, 8, 12, 18, and 24 hours post-dose.</time_frame>
        <population>Per Protocol Population, defined as all subjects who have received all study medications and are evaluable for all treatments.</population>
        <group_list>
          <group group_id="O1">
            <title>Primatene Mist, E004</title>
            <description>Participants who dosed with Primatene Mist.&#xD;
Epinephrine (0.125 mg/inhalation): Participants will self-administer 2 inhalations of Epinephrine (0.125 mg/inhalation) for a total dosage of 0.25 mg.</description>
          </group>
          <group group_id="O2">
            <title>Epinephrine Injection Auto-Injector (Generic of EpiPen)</title>
            <description>Participants who were dosed with an Epinephrine Injection Auto-Injector.&#xD;
Epinephrine Injection Auto-Injector (0.3mg/0.3mL): Participants will receive an intramuscular injection of Epinephrine via Auto-Injector (0.30 mg of epinephrine solution in 0.30 mL). The 0.30 mL dose will be given perpendicularly as a single deep intramuscular injection into the anterolateral aspect of the thigh.</description>
          </group>
          <group group_id="O3">
            <title>Albuterol HFA</title>
            <description>Participants who dosed with Albuterol HFA.&#xD;
Albuterol Sulfate (0.09 mg/inhalation): Participants will self-administer 2 inhalations of Albuterol Sulfate (0.09 mg/inhalation) for a total dosage of 0.18 mg.</description>
          </group>
        </group_list>
        <measure>
          <title>t[1/2], Terminal Elimination Half-life of Albuterol or Epinephrine</title>
          <description>Pharmacokinetic (PK) blood samples will be collected starting 30 minutes before dose and until 24 hours after dose. Plasma will be isolated for analyzing the concentrations of Albuterol and Epinephrine.</description>
          <population>Per Protocol Population, defined as all subjects who have received all study medications and are evaluable for all treatments.</population>
          <units>min</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.1" spread="5.2"/>
                    <measurement group_id="O2" value="138.8" spread="4.0"/>
                    <measurement group_id="O3" value="420.7" spread="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From signing of consent until follow-up (approximately 4 weeks)</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Primatene Mist, E004</title>
          <description>Participants who dosed with Primatene Mist.&#xD;
Epinephrine (0.125 mg/inhalation): Participants will self-administer 2 inhalations of Epinephrine (0.125 mg/inhalation) for a total dosage of 0.25 mg.</description>
        </group>
        <group group_id="E2">
          <title>Epinephrine Injection Auto-Injector (Generic of EpiPen)</title>
          <description>Participants who were dosed with an Epinephrine Injection Auto-Injector.&#xD;
Epinephrine Injection Auto-Injector (0.3mg/0.3mL): Participants will receive an intramuscular injection of Epinephrine via Auto-Injector (0.30 mg of epinephrine solution in 0.30 mL). The 0.30 mL dose will be given perpendicularly as a single deep intramuscular injection into the anterolateral aspect of the thigh.</description>
        </group>
        <group group_id="E3">
          <title>Albuterol HFA</title>
          <description>Participants who dosed with Albuterol HFA.&#xD;
Albuterol Sulfate (0.09 mg/inhalation): Participants will self-administer 2 inhalations of Albuterol Sulfate (0.09 mg/inhalation) for a total dosage of 0.18 mg.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>3</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection Site Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="27"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Amphastar Pharmaceuticals, Inc.</name_or_title>
      <organization>Amphastar Pharmaceuticals, Inc.</organization>
      <phone>(909) 980-9484</phone>
      <email>info@amphastar.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

